444 related articles for article (PubMed ID: 25792708)
21. Low-dose budesonide for maintenance of clinical remission in collagenous colitis: a randomised, placebo-controlled, 12-month trial.
Münch A; Bohr J; Miehlke S; Benoni C; Olesen M; Öst Å; Strandberg L; Hellström PM; Hertervig E; Armerding P; Stehlik J; Lindberg G; Björk J; Lapidus A; Löfberg R; Bonderup O; Avnström S; Rössle M; Dilger K; Mueller R; Greinwald R; Tysk C; Ström M;
Gut; 2016 Jan; 65(1):47-56. PubMed ID: 25425655
[TBL] [Abstract][Full Text] [Related]
22. Long-term budesonide treatment of collagenous colitis: a randomised, double-blind, placebo-controlled trial.
Bonderup OK; Hansen JB; Teglbjaerg PS; Christensen LA; Fallingborg JF
Gut; 2009 Jan; 58(1):68-72. PubMed ID: 18669576
[TBL] [Abstract][Full Text] [Related]
23. Every-other-day Dosing of Oral Viscous Budesonide Is not Effective in the Management of Eosinophlic Esophagitis.
Rubinstein E; Hait EE; Mitchell PD; Lee JJ
J Pediatr Gastroenterol Nutr; 2018 Mar; 66(3):395-397. PubMed ID: 28837508
[TBL] [Abstract][Full Text] [Related]
24. Once-daily budesonide MMX® extended-release tablets induce remission in patients with mild to moderate ulcerative colitis: results from the CORE I study.
Sandborn WJ; Travis S; Moro L; Jones R; Gautille T; Bagin R; Huang M; Yeung P; Ballard ED
Gastroenterology; 2012 Nov; 143(5):1218-1226.e2. PubMed ID: 22892337
[TBL] [Abstract][Full Text] [Related]
25. Retrospective Comparison of Fluticasone Propionate and Oral Viscous Budesonide in Children With Eosinophilic Esophagitis.
Fable JM; Fernandez M; Goodine S; Lerer T; Sayej WN
J Pediatr Gastroenterol Nutr; 2018 Jan; 66(1):26-32. PubMed ID: 28489670
[TBL] [Abstract][Full Text] [Related]
26. Comparisons of Fluticasone to Budesonide in the Treatment of Eosinophilic Esophagitis.
Albert D; Heifert TA; Min SB; Maydonovitch CL; Baker TP; Chen YJ; Moawad FJ
Dig Dis Sci; 2016 Jul; 61(7):1996-2001. PubMed ID: 27093866
[TBL] [Abstract][Full Text] [Related]
27. Long-Term Treatment of Eosinophilic Esophagitis With Budesonide Oral Suspension.
Dellon ES; Collins MH; Katzka DA; Mukkada VA; Falk GW; Morey R; Goodwin B; Eisner JD; Lan L; Desai NK; Williams J; Hirano I;
Clin Gastroenterol Hepatol; 2022 Jul; 20(7):1488-1498.e11. PubMed ID: 34182150
[TBL] [Abstract][Full Text] [Related]
28. Efficacy and Safety of Budesonide, vs Mesalazine or Placebo, as Induction Therapy for Lymphocytic Colitis.
Miehlke S; Aust D; Mihaly E; Armerding P; Böhm G; Bonderup O; Fernández-Bañares F; Kupcinskas J; Munck LK; Rehbehn KU; Nacak T; Greinwald R; Münch A;
Gastroenterology; 2018 Dec; 155(6):1795-1804.e3. PubMed ID: 30195447
[TBL] [Abstract][Full Text] [Related]
29. Randomised clinical trial: the safety and tolerability of fluticasone propionate orally disintegrating tablets versus placebo for eosinophilic oesophagitis.
Hirano I; Safroneeva E; Roumet MC; Comer GM; Eagle G; Schoepfer A; Falk GW
Aliment Pharmacol Ther; 2020 Apr; 51(8):750-759. PubMed ID: 32149424
[TBL] [Abstract][Full Text] [Related]
30. Once versus three times daily dosing of oral budesonide for active Crohn's disease: a double-blind, double-dummy, randomised trial.
Dignass A; Stoynov S; Dorofeyev AE; Grigorieva GA; Tomsová E; Altorjay I; Tuculanu D; Bunganič I; Pokrotnieks J; Kupčinskas L; Dilger K; Greinwald R; Mueller R;
J Crohns Colitis; 2014 Sep; 8(9):970-80. PubMed ID: 24534142
[TBL] [Abstract][Full Text] [Related]
31. Once-daily budesonide MMX in active, mild-to-moderate ulcerative colitis: results from the randomised CORE II study.
Travis SP; Danese S; Kupcinskas L; Alexeeva O; D'Haens G; Gibson PR; Moro L; Jones R; Ballard ED; Masure J; Rossini M; Sandborn WJ
Gut; 2014 Mar; 63(3):433-41. PubMed ID: 23436336
[TBL] [Abstract][Full Text] [Related]
32. Pooled Phase 2 and 3 Efficacy and Safety Data on Budesonide Oral Suspension in Adolescents with Eosinophilic Esophagitis.
Mukkada VA; Gupta SK; Gold BD; Dellon ES; Collins MH; Katzka DA; Falk GW; Williams J; Zhang W; Boules M; Hirano I; Desai NK
J Pediatr Gastroenterol Nutr; 2023 Dec; 77(6):760-768. PubMed ID: 37718471
[TBL] [Abstract][Full Text] [Related]
33. Swallowed Fluticasone Propionate Is an Effective Long-Term Maintenance Therapy for Children With Eosinophilic Esophagitis.
Andreae DA; Hanna MG; Magid MS; Malerba S; Andreae MH; Bagiella E; Chehade M
Am J Gastroenterol; 2016 Aug; 111(8):1187-97. PubMed ID: 27325220
[TBL] [Abstract][Full Text] [Related]
34. Eosinophilic esophagitis: treatment with oral viscous budesonide.
Zur E
Int J Pharm Compd; 2012; 16(4):288-93. PubMed ID: 23050387
[TBL] [Abstract][Full Text] [Related]
35. Budesonide as induction therapy for incomplete microscopic colitis: A randomised, placebo-controlled multicentre trial.
Münch A; Mihaly E; Nagy F; Madisch A; Kupčinskas J; Miehlke S; Bohr J; Bouma G; Guardiola J; Belloc B; Shi C; Aust D; Mohrbacher R; Greinwald R; Munck LK
United European Gastroenterol J; 2021 Sep; 9(7):837-847. PubMed ID: 34414678
[TBL] [Abstract][Full Text] [Related]
36. Safety of an investigational formulation of budesonide (budesonide oral suspension) for eosinophilic oesophagitis: an integrated safety analysis of six phase 1-3 clinical trials.
Hirano I; Dellon ES; Gupta SK; Katzka DA; Collins MH; Wojtowicz AM; Terreri B; Zhang W; Boules M; Bhatia S; Desai NK
Aliment Pharmacol Ther; 2023 May; 57(10):1117-1130. PubMed ID: 36890134
[TBL] [Abstract][Full Text] [Related]
37. Swallowed topical steroid therapy for eosinophilic oesophagitis in children: practical, evidence-based guidance by the BSPGHAN Eosinophilic Oesophagitis Working Group.
Chan J; Flynn DM; Gordon M; Parmar R; Moolenschot K; Jackman L; Gaynor E; Epstein J; Cordell A; Kannappan H; Furman M; Thompson J; Gasparetto M; Auth MKH
BMJ Paediatr Open; 2024 May; 8(1):. PubMed ID: 38782481
[TBL] [Abstract][Full Text] [Related]
38. Comparison of 2 delivery vehicles for viscous budesonide to treat eosinophilic esophagitis in children.
Rubinstein E; Lee JJ; Fried A; Logvinenko T; Ngo P; McDonald D; Hait EJ
J Pediatr Gastroenterol Nutr; 2014 Sep; 59(3):317-20. PubMed ID: 24821535
[TBL] [Abstract][Full Text] [Related]
39. Comparison of the efficacy of ciclesonide 160 microg QD and budesonide 200 microg BID in adults with persistent asthma: a phase III, randomized, double-dummy, open-label study.
Niphadkar P; Jagannath K; Joshi JM; Awad N; Boss H; Hellbardt S; Gadgil DA
Clin Ther; 2005 Nov; 27(11):1752-63. PubMed ID: 16368446
[TBL] [Abstract][Full Text] [Related]
40. Results of ambulatory pH monitoring do not reliably predict response to therapy in patients with eosinophilic oesophagitis.
Francis DL; Foxx-Orenstein A; Arora AS; Smyrk TC; Jensen K; Nord SL; Alexander JA; Romero Y; Katzka DA
Aliment Pharmacol Ther; 2012 Jan; 35(2):300-7. PubMed ID: 22111863
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
